However, in human K562 CML cells as well as patient-derived CML CD34+ cells, no drastically altered Bcr-Abl or STAT5 phosphorylation was evident upon Ibr treatment. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.